Research Paper Volume 13, Issue 17 pp 21102—21121

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK

BTK expression in the MCL patients and the benign lymphoid tissues. (A) ×100 magnification and (B) ×400 magnification, Representative patterns of BTK expressing limitedly in the germinal center cells of the mantle zone in the tonsils. (C) ×100 magnification and (D) ×400 magnification, Representative patterns of low BTK expression with less than one-quarter positive staining proportion in the MCL patient tissues. (E) ×100 magnification and (F) ×400 magnification, Representative patterns of high BTK expression with widely broken and disappeared germinal center in the MCL patient tissues.

Figure 1. BTK expression in the MCL patients and the benign lymphoid tissues. (A) ×100 magnification and (B) ×400 magnification, Representative patterns of BTK expressing limitedly in the germinal center cells of the mantle zone in the tonsils. (C) ×100 magnification and (D) ×400 magnification, Representative patterns of low BTK expression with less than one-quarter positive staining proportion in the MCL patient tissues. (E) ×100 magnification and (F) ×400 magnification, Representative patterns of high BTK expression with widely broken and disappeared germinal center in the MCL patient tissues.